Journal
ONCOGENE
Volume 38, Issue 33, Pages 6095-6108Publisher
SPRINGERNATURE
DOI: 10.1038/s41388-019-0862-y
Keywords
-
Funding
- National Institutes of Health [CA016672, UH3TR000943, P50 CA217685, P50 CA098258, R35 CA209904]
- Ovarian Cancer Research Fund, Inc.
- Blanton-Davis Ovarian Cancer Research Program
- American Cancer Society Research Professor Award
- Frank McGraw Memorial Chair in Cancer Research
- CPRIT [DP150091]
- Foundation for Women's Cancer Grant
- SPORE in Ovarian Cancer at MD Anderson [P50 CA217685]
Ask authors/readers for more resources
Current anti-angiogenic therapy for cancer is based mainly on inhibition of the vascular endothelial growth factor pathway. However, due to the transient and only modest benefit from such therapy, additional approaches are needed. Deregulation of microRNAs (miRNAs) has been demonstrated to be involved in tumor angiogenesis and offers opportunities for a new therapeutic approach. However, effective miRNA-delivery systems are needed for such approaches to be successful. In this study, miRNA profiling of patient data sets, along with in vitro and in vivo experiments, revealed that miR-204-5p could promote angiogenesis in ovarian tumors through THBS1. By binding with scavenger receptor class B type 1 (SCARB1), reconstituted high-density lipoprotein-nanoparticles (rHDL-NPs) were effective in delivering miR-204-5p inhibitor (miR-204-5p-inh) to tumor sites to suppress tumor growth. These results offer a new understanding of miR-204-5p in regulating tumor angiogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available